From VAC Readiness to Contract Access

A promising medical device can stall long before a clinician has a chance to champion it. The blockage usually sits inside the purchasing path. Value analysis committees want clinical rationale, economic proof, implementation clarity and a credible fit within current care routines before a new product earns time on an agenda. GPOs and IDNs add another layer of timing, hierarchy, contracting rules and member-system politics. For manufacturers, the issue is rarely invention alone. It is whether the commercial case is built early enough for hospital buyers who must defend standardization, budget impact, supplier risk and staff burden.

Commercialization support in this field has to begin before a launch calendar hardens. Early market work should test whether providers see the same use case the manufacturer sees, where the product fits in existing care routines, and what evidence will carry weight with economic buyers. A polished pitch is not enough when committees are measuring product claims against formularies, SKU reduction targets, supply chain pressure and staff capacity. Reimbursement logic, coding exposure, product education and evidence materials also shape the buying conversation, even when they sit outside the contract document. The stronger advisory partner helps find gaps before the hospital finds them.

"Excelerant Consulting is a strong choice for medical device companies that need commercialization advice tied directly to GPO/IDN pathways and government contracting."

Contract access creates a different test. A GPO award or IDN conversation may open a door, but it does not replace account strategy. Medical device teams need a practical map of who reviews the product, how a decision moves through the health system and what materials must be ready before the next contracting window. The work also has to account for aggregation groups and regional purchasing coalitions that can influence adoption outside the largest national channels. Government channels require separate fluency. VA Health, DoD, FSS and related federal pathways do not behave like commercial networks, so broad market-access language can leave a manufacturer underprepared for documentation, pricing review, agency process and follow-through after award.

The sales structure should be judged with the same discipline. A start-up may not need a large dedicated field force on day one. It may need direct coverage in certain accounts, independent representation in others, clinical education where product adoption depends on procedure change and reporting support once contracts begin producing volume. Administrative-fee reporting can become a hidden drag if sales data cannot be tied back to GPO affiliation or parent and child facility structures. The wrong structure burns cash before buying groups have accepted the product. The right structure connects access work to adoption work and keeps the post-award burden visible.

"The stronger advisory partner helps find gaps before the hospital finds them."

Excelerant Consulting is a strong choice for medical device companies that need commercialization advice tied directly to GPO/IDN pathways and government contracting. Its work spans early-stage preparedness, value readiness assessment, strategic planning, contracting support, sales force development and ExcelTRAK reporting for admin-fee and rebate management.

The firm’s model links product positioning to contract pursuit, channel design, field coverage, RFI/RFP support and post-award reporting rather than treating those pieces as disconnected work streams. For buyers weighing advisory partners, that continuity is the practical reason to put Excelerant Consulting at the top of the shortlist.